MX2009012523A - Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas. - Google Patents

Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.

Info

Publication number
MX2009012523A
MX2009012523A MX2009012523A MX2009012523A MX2009012523A MX 2009012523 A MX2009012523 A MX 2009012523A MX 2009012523 A MX2009012523 A MX 2009012523A MX 2009012523 A MX2009012523 A MX 2009012523A MX 2009012523 A MX2009012523 A MX 2009012523A
Authority
MX
Mexico
Prior art keywords
methods
compositions useful
nephrotoxic
reducing nephrotoxicity
drug
Prior art date
Application number
MX2009012523A
Other languages
English (en)
Inventor
Vernon D Rowe
Original Assignee
Verrow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verrow Pharmaceuticals Inc filed Critical Verrow Pharmaceuticals Inc
Publication of MX2009012523A publication Critical patent/MX2009012523A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones y métodos para reducir daño renal causado por fármacos nefrotóxicos. La invención proporciona composiciones que comprenden una ciclodextrina sustituida, un fármaco nefrotóxico y un portador farmacéuticamente aceptable, en donde la ciclodextrina está presente en una cantidad efectiva para sustancialmente inhibir el efecto nefrotóxico del fármaco.
MX2009012523A 2007-05-25 2008-05-22 Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas. MX2009012523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/753,883 US7658913B2 (en) 2005-11-28 2007-05-25 Compositions useful for reducing nephrotoxicity and methods of use thereof
PCT/US2008/064489 WO2008147856A1 (en) 2007-05-25 2008-05-22 Compositions useful for reducing nephrotoxicity and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009012523A true MX2009012523A (es) 2010-02-18

Family

ID=40076731

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012523A MX2009012523A (es) 2007-05-25 2008-05-22 Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.

Country Status (10)

Country Link
US (5) US7658913B2 (es)
EP (1) EP2162138B1 (es)
JP (1) JP5416095B2 (es)
KR (1) KR20100023901A (es)
CN (1) CN101686991A (es)
AU (1) AU2008256808B2 (es)
BR (1) BRPI0812166A2 (es)
CA (1) CA2687574C (es)
MX (1) MX2009012523A (es)
WO (1) WO2008147856A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
EP2152078B8 (en) 2007-04-27 2021-03-17 CyDex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US8236782B2 (en) 2009-05-13 2012-08-07 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
EP2854531A4 (en) * 2012-05-30 2016-03-23 Verrow Pharmaceuticals Inc STABILIZED FORMULATIONS CONTAINING IODIZED CONTRAST AGENTS AND CYCLODEXTRINS
JP6239282B2 (ja) * 2013-06-28 2017-11-29 日本食品化工株式会社 腎不全改善剤
WO2015147018A1 (ja) * 2014-03-28 2015-10-01 テルモ株式会社 炎症性自己免疫疾患治療用の注射用水性製剤
CN104280478B (zh) * 2014-11-03 2016-03-30 天津中医药大学 内源性小分子物质在快速检测肾毒性方面的应用
EP3313519B1 (en) * 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat inhibitors for the treatment of congenital myopathies
CN110831588B (zh) * 2017-05-03 2023-06-27 锡德克斯药物公司 包含环糊精和白消安的组合物
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN114982708A (zh) * 2022-05-11 2022-09-02 成都医学院第一附属医院 一种小鼠造影剂肾病模型及其构建方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US4247535A (en) 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4654325A (en) 1984-05-24 1987-03-31 Selenke William M Medicament for reducing nephrotoxicity caused by positively charged agents such as aminoglycosides and methods of use thereof
DK500185A (da) * 1984-11-02 1986-05-03 Johnson Matthey Plc Oploeseliggjort platinforbindelse
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
JPH01501478A (ja) * 1986-11-25 1989-05-25 インスティテュト　オルガニチェスコゴ　シンテザ　アカデミイ　ナウク　ラトビイスコイ　エスエスアール ９―置換グアニン
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5441944A (en) 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5010092A (en) * 1989-12-22 1991-04-23 Wisconsin Alumni Research Foundation Protection against chemically-induced kidney damage by methimazole
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
US5780446A (en) * 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
FR2754270B1 (fr) 1996-10-07 1998-12-24 Goemar Lab Sa Genes codant pour des iota-carraghenases et leur utilisation pour la production d'enzymes de biodegradation des carraghenanes
ATE308337T1 (de) * 1997-03-15 2005-11-15 Nakamura Toshikazu Hgf zur behandlung von akutem nierenversagen
JPH11100401A (ja) 1997-07-30 1999-04-13 Kikkoman Corp 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
JP3229286B2 (ja) * 1999-04-02 2001-11-19 インターナショナル・ビジネス・マシーンズ・コーポレーション プリント回路基板の製造方法
ES2206254T3 (es) * 1999-07-01 2004-05-16 Italfarmaco S.P.A. Complejos de paroxetina con ciclodextrinas o derivados de ciclodextrinas.
GB9921954D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
GB9921958D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
KR100358855B1 (ko) * 2000-02-29 2002-10-31 광주과학기술원 사이클로덱스트린 또는 그 유도체와 조영제의 포접 착체형성 방법
KR100362080B1 (ko) 2000-03-29 2002-11-23 광주과학기술원 고리 올리고당과 그들의 유도체를 이용한 조영제의 새로운포접 착체
SI1278549T1 (sl) * 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
WO2002089805A2 (en) 2001-05-03 2002-11-14 Midamerica Neuroscience Research Foundation Use of regularly scheduled high dose intravenous methotrexate therapy
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
WO2003080080A1 (en) * 2002-03-21 2003-10-02 Regents Of The University Of Minnesota Cyclodextrin compositions and methods of treating viral infections
NZ536908A (en) 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
US20040048871A1 (en) 2002-09-09 2004-03-11 Rowe Vernon D. Use of high dose intravenous methotrexate, with leucovorin rescue, to treat early multiple sclerosis and other diseases of the central nervous system
JP2004235128A (ja) 2002-12-04 2004-08-19 Dainippon Printing Co Ltd 有機ｅｌ素子およびその製造方法
GB0404487D0 (en) * 2004-02-28 2004-03-31 Protherics Molecular Design Lt Use of enzyme
GB0519391D0 (en) * 2005-09-22 2005-11-02 Aion Diagnostics Ltd Imaging agents
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
CN101355952B (zh) * 2005-11-28 2012-03-21 韦罗制药有限公司 用于减少肾毒性的组合物及其使用方法
JP4008481B2 (ja) * 2006-08-21 2007-11-14 独立行政法人科学技術振興機構 腎臓の薬物排泄機能に関与する有機アニオントランスポーター

Also Published As

Publication number Publication date
BRPI0812166A2 (pt) 2015-07-07
CN101686991A (zh) 2010-03-31
CA2687574C (en) 2016-04-12
AU2008256808B2 (en) 2013-07-04
US20070270380A1 (en) 2007-11-22
EP2162138A4 (en) 2010-07-28
US8277779B2 (en) 2012-10-02
EP2162138B1 (en) 2013-08-28
US20100093664A1 (en) 2010-04-15
AU2008256808A2 (en) 2010-01-07
EP2162138A1 (en) 2010-03-17
US8574551B2 (en) 2013-11-05
KR20100023901A (ko) 2010-03-04
JP5416095B2 (ja) 2014-02-12
AU2008256808A1 (en) 2008-12-04
US20120321564A1 (en) 2012-12-20
JP2010528045A (ja) 2010-08-19
CA2687574A1 (en) 2008-12-04
WO2008147856A1 (en) 2008-12-04
US20110028413A1 (en) 2011-02-03
US7658913B2 (en) 2010-02-09
US20110027390A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
MX2009012523A (es) Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.
MY154909A (en) Novel thiophene derivatives
UA96449C2 (en) Stable laquinimod preparations
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
GEP20125487B (en) Organic compounds and their use
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
UA108105C2 (ru) Азотсодержащие гетероарильные соединения
IL192948A0 (en) Novel pyridine derivatives
MX2012003082A (es) Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
MY153921A (en) Aminopyrazole derivatives
MY139913A (en) Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
NZ606123A (en) Use of binders for manufacturing storage stable formulations
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
MX342440B (es) Derivados fluorados de aminotriazol.
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
UA111599C2 (uk) Композиція каспофунгіну
MY152885A (en) Medicament containing fluoroquinolones
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
JO3112B1 (ar) تركيبة دوائية سريعة التحلل
SG170037A1 (en) Compositions useful for reducing nephrotoxicity and methods of use thereof
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
TN2014000060A1 (en) Benzothiazolone compound

Legal Events

Date Code Title Description
FG Grant or registration